With issues of error in packaging, North American division company of Glenmark Pharmaceuticals Ltd. i. e. Glenmark Generics Inc. has issued an immediate recall over seven lots of contraceptive tablets, all from the US market.
In its announcements, Glenmark Generics Inc. said that it has issued a voluntary, nationwide, consumer-level recall in the entire US market of all the seven lots of oral contraceptive tablets that it has sold in the country including in the lots: Norgestimate and Ethinyl Estradiol tablets USP, 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035mg.
The company said that they noticed some packaging errors in few of the selected blisters, which could have reversed the weekly tablet orientation, thereby publishing the lot number and expiry date only on the outer pouch of the tablets.
Following their announcement of the recall, the company has suggested all the people to identify this packaging error (in only the seven lots mentioned) prior making their buy and also they have pointed all those blisters that are not mentioning any lot number and expiry date on their cover as subjected to recall.
Glenmark also cleared in its announcement that the packaging errors could have also resulted in not giving correct information about the daily regimen for these oral contraceptives, which cannot give women adequate contraception, thereby pushing them at higher risk for unintended pregnancy as the product (in talks for recall) is an oral contraceptive that is being sold in the market to enable women prevent their pregnancy.
The company has urged all the wholesalers and retail pharmacies in the US, who have been supplied with the contraceptive tablet lots between September 21, 2011 and December 30, 2011, to help the company in its recall of the product.
- Postage Prices will Decrease from Sunday; USPS not too Happy About It
- Marriott and Starwood Hotels & Resorts Worldwide Inc Shareholders Approve to $14.41 Sales Deal
- UK plan to impose additional tax on sugary drinks
- Obesity during pregnancy may increase risk of very ‘large babies’
- Dropping Sales at Gap’s Key Brands hurt the Company’s Shares